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ABSTRACT 
Objective: Phenytoin displays nonlinear pharmacokinetics due to the saturation of its’ metabolizing enzymes, thus making dosing adjustments a 
challenge in clinical practice. However, data on the pharmacokinetic parameters of phenytoin in pediatric patients with epilepsy in Thailand remain 
lacking. This study aimed to determine the pharmacokinetic parameters of phenytoin, and the factors influencing them in epileptic Thai children 
using therapeutic drug monitoring data.  
Methods: Steady state phenytoin plasma concentrations were collected from 96 Thai children with epilepsy aged ≤ 15 y. For individuals having a 
single steady-state concentration (Css) on one dosage, the Vmax was determined by fixing Km = 4.5 mg/l. For patients with two values for Css with 
different dosages, the Ludden method was used to determine Vmax and Km. Influences on Vmax and Km by demographic factors including age, sex, 
weight, serum albumin, and the use of CYP2C9 inducers (carbamazepine, phenobarbital, folic acid, and vigabatrin) and inhibitors (valproic acid and 
topiramate) were determined by linear mixed-effects regression. 
Results: The majority of patients had sub-therapeutic plasma concentrations of phenytoin. The Vmax and Km were estimated to be 9.84 mg/kg/d 
and 2.32 mg/l, respectively. Age and weight significantly influenced Vmax, whereas Km had no significant influencing factors.  
Conclusion: The Vmax estimated in this study is different from other populations previously reported. Our results suggest that increased phenytoin 
dosages may be required to achieve optimal concentrations due to the sub-therapeutic concentrations reported here. The results from this study 
are beneficial for phenytoin dosage individualization in Thai children. 
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Phenytoin is the anti-epileptic drug of choice for both generalized 
and partial seizures in children [1]. Phenytoin is known to have a 
narrow therapeutic range of 10-20 mg/l and exhibit nonlinear 
pharmacokinetics with a wide inter-individual variability in plasma 
concentrations. Thus, small changes in the dosing of phenytoin may 
result in disproportionately large changes in plasma concentrations. 
Plasma concentrations below the therapeutic window may lead to 
treatment failure, while concentrations above may result in toxicity. 
Therefore, dosage adjustments to maintain plasma concentrations 
within the therapeutic range are necessary. Phenytoin 
pharmacokinetics follow Michaelis-Menten kinetics in the 
therapeutic dose range [2]. To individualize a phenytoin dosage 
regimen, it is important to know certain pharmacokinetic 
parameters of phenytoin, including the maximum rate of 
metabolism (Vmax) and the Michaelis-Menten constant (Km). High 
variability in the values of Vmax and Km has been reported among 
populations [3-10]. Several factors have been identified to impact 
the variability of these parameters, including age, sex, weight, serum 
albumin, and drugs that either induce or inhibit the activity of the 
enzyme CYP2C9 [3-10]. However, the values of Vmax and Km, as 
well as any factors influencing them, have never been studied in a 
population of Thai children.  
Therefore, this study aimed to determine Vmax and Km in Thai 
children with epilepsy and identify the impact of factors on these 
pharmacokinetic parameters. 
A cross-sectional analytical study was performed at Maharaj Nakorn 
Chiang Mai hospital from January 2015 to December 2018. 
Therapeutic drug monitoring data from 96 Thai children aged ≤ 15 y 
and diagnosed with epilepsy was collected from the Therapeutic 
Drug Monitoring unit. All the patients had been receiving phenytoin 
treatment for at least 7 d before the blood collection. Phenytoin was 
given as monotherapy or concomitant with other antiepileptic drugs 
serving as either CYP2C9 inducers (carbamazepine, phenobarbital, 
folic acid, and vigabatrin) or CYP2C9 inhibitors (valproic acid and 
topiramate). A total of  76 patients had a single steady-state 
concentration (Css) on a single dosage, whereas 20 patients had two 
Css values with two different dosages. Patients with laboratory 
evidence of renal or hepatic disease, as well as patients with 
incomplete information regarding phenytoin dosing, sampling history, 
or laboratory data were excluded. Data collection included phenytoin 
dosing history (dosage regimen and dosing schedule), total phenytoin 
concentration, co-medications and demographic data including age, 
gender, body weight and laboratory data (i.e., AST, ALT, serum 
albumin, total bilirubin and serum creatinine). The study was 
approved by the Research Ethics Committee Faculty of Medicine 
Chiang Mai University, Chiang Mai, Thailand (NONE-2561-05300). 
The pharmacokinetic parameters (Vmax and Km) of each patient 
were determined by two methods: for patients having two Css 
values with different dosages, Vmax and Km were determined by 
Ludden’s method [11]. Using Ludden’s method, on the graph of daily 
dose vs. daily dose/Css, Vmax and–Km are calculated as the 
intercept and slope, respectively. For patients with one Css on one 
dosage, Vmax was determined using the following equation and 





Where Vmax is the maximum rate of metabolism, Km is the 
Michaelis-Menten constant, MD is the maintenance dose, and Css is 
the steady-state concentration. 
Descriptive data were presented as the mean±standard deviation 
(SD) or as the median±interquartile range (IQR) depending on the 
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data distribution. The comparison of Vmax and Km between age 
groups (1 mo–6 y and 7–15 y) was performed using ANOVA or the 
Wilcoxon rank-sum test depending on the normality of the data. The 
influence of demographic factors including age, sex, weight, serum 
albumin, CYP2C9 inducers (carbamazepine, phenobarbital, folic acid, 
and vigabatrin) and CYP2C9 inhibitors (valproic acid and 
topiramate) on Vmax and Km were determined using linear mixed-
effects regression. Data analysis was performed using STATA 
version 14.0 (Stata Statistical Software: Release 14. College Station, 
TX: StataCorp LP.) 
A total of 158 blood samples from 96 Thai children with epilepsy were 
included in the analysis. This included 20 patients with two Css values 
on two dosages and 76 patients with a total of 118 Css values collected 
on a single dosage. Fifty-nine of the patients (61.46%) were male. The 
medians for age and weight were 7 y and 20.9 kg, respectively. The 
mean serum albumin collected from 28 patients was 4.43 g/dl. The 
median phenytoin concentration was 2.88 mg/l. approximately 33.5% 
of the patients were receiving phenytoin along with CYP2C9 inducers 
and 24% were receiving co-treatment with CYP2C9 inhibitors. A 
summary of the demographic information is represented in table 1. 
  
Table 1: Summary of patient demographics (N=96 patients) 
 Frequency (%) 
Female, n (%) 37 (38.5) 
Inhibitors, n (%): 33 (34.38) 
Valproic acid  23 (23.96) 
Topiramate  13 (13.54) 
Inducers, n (%): 21 (21.88) 
Carbamazepine  5 (5.21) 
Phenobarbital 7 (7.29) 
Folic acid  11 (11.46) 
Vigabatrin  1 (1.04) 
 Mean/median (SD/IQR) 
Age (y), mean (SD)  7 (8) 
PHT serum concentration (mg/l), mean (SD) 2.88 (1.48) 
Dose of PHT (mg/kg/d), median (IQR)  4.86 (1.72) 
Serum albumin (g/dl)‡, median (IQR)  4.43 (0.48) 
‡ Serum albumin was obtained from 28 patients 
 
Using a therapeutic index for phenytoin of 10-20 mg/l, our data 
shows that only 12 blood samples (7.6%) from 9 patients had 
phenytoin concentrations within the therapeutic range. Sub-
therapeutic concentrations were found in 141 blood samples (from 
89 patients) and supra-therapeutic concentrations in 5 blood 
samples (from 5 patients) (table 2). 
 
Table 2: Serum phenytoin concentration range 
 Blood samples (n=158) (%) 
Sub-therapeutic range (<10 mg/l) 141 (89.2%) 
Therapeutic range (10-20 mg/l)  12 (7.6%) 
Supra-therapeutic range (>20 mg/l)  5 (3.2%) 
 
The median for Vmax and Km from 96 patients was 2.32 mg/l 
and 9.84 mg/kg/d, respectively. When the median Vmax or Km 
was compared between age groups (1 mo–6 y vs. 7–15 y), the 
Km of the younger group was significantly lower than that of the 
older age group (1.21 vs 3.42 mg/l, p<0.001). Meanwhile, the 
Vmax of the younger age group was significantly higher than the 
Vmax of the older age group (14.65 vs 8.21 mg/kg/d, p<0.001) 
(table 3). 
  
Table 3: Pharmacokinetic parameters of phenytoin according to age group 
Parameters Median (IQR) p-valuea 
Km (mg/l) (n=40)  2.32 (3.65)   
 1 mo–6 y (n=16) 1.21 (1.61)  <0.001 
 7–15 y (n=24)  3.42 (4.30)   
Vmax (mg/kg/d) (n=158) 9.84 (8.28)   
 1 mo–6 y (n=70) 14.65 (13.78)  <0.001 
 7–15 y (n=88)  8.21 (4.11)   
a P-value was calculated using wilcoxon rank-sum test. 
 
Among all demographic factors tested for influence on Vmax and 
Km, we found age and weight to significantly impact Vmax. None of 
the factors tested were found to significantly influence Km. Vmax 
can thus be described by the following equation:  
Vmax=173.32-11.95 ×(Age)+7.94×(Weight) 
The pharmacokinetics of phenytoin show high interindividual 
variability [3-10]; therefore individualizing a patient dosage 
regimen to obtain optimal plasma concentrations is crucial. Knowing 
the pharmacokinetic parameters of phenytoin, specifically, Vmax 
and Km, is important for optimizing phenytoin dosing. This study 
aimed to determine the Vmax and Km in Thai pediatric patients. 
Additionally, factors influencing these parameters were also 
investigated. 
Sub-therapeutic concentrations of phenytoin are commonly 
observed in pediatric populations, although standard dosages of 
phenytoin are given [3, 12, 13]. A previous study found 43% of 
children studied had sub-therapeutic concentrations, this was 
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compared to 33% in adults and 10% in elderly subjects [13]. 
Another study showed 44% of phenytoin concentrations measured 
were below the therapeutic range [12]. In the current study, most of 
the patients (89%) had sub-therapeutic concentrations of 
phenytoin, while only 7.6% had phenytoin concentrations within the 
therapeutic range. A study by Suzuki Y. et al. recommended that 
phenytoin dosing in children be increased ≥ 8 mg/kg/ d to obtain 
optimal phenytoin concentrations [3]. Therefore, increased 
phenytoin doses may also be required to achieve therapeutic 
concentrations in Thai children.  
Our results calculated the median value of Km obtained from 20 
patients to be 2.32 mg/l. This value is lower than a value for Km 
previously estimated for Thai children [14]. Of note, the previous 
study was performed in Thai children receiving phenytoin 
exclusively as monotherapy. Our reported value for Km is also lower 
than values previously estimated for Malaysian and Iranian 
populations but similar to a value reported for a Japanese 
population [4, 7, 8, 12]. The different values for Km seen in these 
studies could be due to the different baseline characteristics of the 
patients enrolled in those studies, as well as the different methods 
used for obtaining the pharmacokinetic parameters. Taken together, 
these results confirm that Km values vary among ethnicities. 
When Km values were compared between age groups (1 mo-6 y vs. 
7-15 y), Km was found to be statistically lower in the 1 mo-6 y 
group. This difference in Km between younger and older patients is 
in agreement with previous studies showing that Km tends to be 
lower in children, especially those aged between 6 and 11 y [15, 16]. 
The estimated Vmax in this study was 9.84 mg/kg/d. This Vmax is 
comparable to a previous report in Malaysian children but higher 
than that found previously in Thai patients [4, 14]. Compared 
between age groups, the Vmax in the the 1 mo-6 y group of patients 
was significantly higher than in the 7-15 y group (14.65 vs. 8.21 
mg/kg/d, respectively). Significant differences in Vmax between age 
groups can be attributed to increased activity by CYP2C9, an enzyme 
responsible for the metabolism of phenytoin primarily in younger 
children compared to adolescents [10, 17].  
Several factors may affect the pharmacokinetics of phenytoin 
including age, weight, race, albumin, and other co-medications. Our 
results show that advanced age is associated with a decreased Vmax, 
consistent with a previous study showing an inverse relationship 
between Vmax and age [3].  
Among the factors we investigated for influence on Vmax, only age 
and weight were found to have a significant impact. Based on these 
results, we adjusted for weight and advanced age was shown to be 
associated with a decreasing Vmax. These results are in agreement 
with a previously published report by Suzuki Y. et al. demonstrating 
that Vmax, reflecting the activity of enzymes, decreases significantly 
with age [3, 15]. Even though the activity of CYP2C9 increases from 
the first week of life onwards, there is evidence that Vmax decreases 
from 14 mg/kg/d in infants to 8 mg/kg/d in adolescents [17]. As 
only a small number of infants were included in our study, any 
potential increase in Vmax during these ages could not be observed 
in our regression analysis. However, some evidence of increased 
activity by CYP2C9 in younger children is present when comparing 
Vmax values between children aged 1 mo-6 y vs. those aged 7-15 y. 
additionally, weight was found to impact Vmax in this study, as 
increased weight was associated with an increased Vmax. This 
positive relationship between Vmax and weight has been observed 
in previous studies [5, 6, 10, 18]. Although there is evidence of lower 
Km values in patients aged<15 y [10, 12], no factors investigated in 
this study were found to be associated with Km. This could be due to 
the small number of patients with two Css values and differing 
dosages from which the Km could be estimated. 
There were some limitations to our current study. First, due to the 
small number of patients having two Css values with different 
dosages, values for Km may not be estimated precisely. Also, no 
factors studied were found to significantly influence Km. Second, as 
the overall sample size was small, the equation developed for 
predicting Vmax could not be validated in this study and should be 
further studied. Third, as there was an insufficient number of 
patients receiving co-medication with either a CYP2C9 inducer or 
inhibitor, the influence of each individual inducer and inhibitor 
could not be quantified. Lastly, this was a retrospective study 
collected from data in patients’ medical records; therefore some 
information may be missing. Previous studies have shown a positive 
correlation between Vmax and albumin, however, the influence of 
serum albumin was not investigated in our study due to the lack of 
serum albumin information for the majority of patients. 
In conclusion, the pharmacokinetic parameters of phenytoin in 
epileptic Thai children differ from those of other ethnicities. Age was 
found to negatively affect the value of Vmax, whereas weight 
positively influenced the value of Vmax. The results from this study 
can be used to help individualize phenytoin dosage regimens in the 
pediatric Thai population.  
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